CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma
IntroductionCAR-T cell therapy, though successful in hematologic malignancies, faces challenges in solid tumors due to limitations of autologous T cells. Cytokine-induced killer (CIK) cells can be given safely across allogeneic barriers and constitute alternative effector cells generated from health...
Saved in:
| Main Authors: | Laura M. Moser, Catrin Heim, Sebastian E. Koschade, Philipp Wendel, Süleyman Bozkurt, Sabine Harenkamp, Hermann Kreyenberg, Michael Merker, Christian Münch, Elise Gradhand, Meike Vogler, Evelyn Ullrich, Halvard Bönig, Jan-Henning Klusmann, Peter Bader, Winfried S. Wels, Eva Rettinger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1485817/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation
by: Catrin Heim, et al.
Published: (2024-06-01) -
Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation
by: Sarah Kayser, et al.
Published: (2024-12-01) -
Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy
by: Franz Rödel, et al.
Published: (2025-07-01) -
Metabolic epigenome targeting hits KMT2A-rearranged acute lymphoblastic leukemia
by: Dirk Heckl, et al.
Published: (2025-06-01) -
Lost in translation: pluripotent stem cell‐derived hematopoiesis
by: Mania Ackermann, et al.
Published: (2015-07-01)